Mediclinic Southern Africa to procure renewable energy from Energy Exchange

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company”, or the “Group”)

3 September 2021

Mediclinic Southern Africa agreement to procure renewable electricity from Energy Exchange

Summary
– Group strategy of becoming carbon neutral by 2030
– Energy Exchange provides Mediclinic Southern Africa with a platform to access
renewable energy from independent power producers at favourable electricity
tariffs

Mediclinic, the diversified international private healthcare services group, announces that its
Southern Africa division has entered into an agreement with Energy Exchange of Southern
Africa (“Energy Exchange”) to procure renewable electricity (“The Agreement”).

As part of the Group’s broad environmental, social and governance strategy, Mediclinic has set
an ambitious target to become carbon neutral by 2030. Procuring renewable energy,
specifically electricity, forms part of this Group strategy. Mediclinic Southern Africa has agreed
to acquire electricity through Energy Exchange, a platform where independent power producers
(“IPPs”) in South Africa can sell renewable energy.

Renewable energy is an emerging industry in South Africa. Energy Exchange is currently the
only platform able to connect businesses with electricity generated by IPPs and which will have
the necessary agreements in place with the state utility provider and local municipalities to
make use of their networks for the distribution of renewable electricity.

While Mediclinic strongly believes that the use of renewable energy is important in ensuring a
healthy planet for future generations, reducing consumption by investing in energy-efficient
equipment and renewable energy sources also assists in mitigating rising electricity costs. In
addition, the Agreement will likely provide an economic benefit as the annual tariff increases
are expected to be inflation-linked.

Commenting today, Dr Ronnie van der Merwe, Group Chief Executive Officer, said:
“Mediclinic is committed to ensuring that every day we improve sustainability by managing our
resources responsibly and efficiently to the benefit of our stakeholders and the environment.

“All divisions are taking steps to reduce their electricity consumption intensity through the
adoption of the ISO 14001:2015 environmental management system. This will lead to improved
operational efficiency of technical installations; the introduction of various new energy-efficient
and renewable technologies; and changes in employee behaviour regarding energy use.

“Mediclinic is proud to participate in this pioneering renewable electricity initiative with Energy
Exchange, enabling us to, over time, add more of our facilities to their network as we strive
towards achieving the Group’s target of being carbon neutral by 2030.”

The Agreement’s total value is limited to £110m. Entering into the Agreement is a smaller-
related party transaction under Listing Rule 11 of the Financial Conduct Authority’s (“FCA”)
United Kingdom (“UK”) Listing Rules, as Remgro Ltd is both a substantial shareholder in
Mediclinic, and one of the founding partners and 35% shareholder in Energy Exchange. The
Agreement is therefore subject to the requirements of FCA Listing Rule 11.1.10R.

Cautionary Statement
This announcement contains certain forward -looking statements relating to the business of the
Company and its subsidiaries, including with respect to the progress, timing and completion of
the Group’s development; the Group’s ability to treat, attract and retain patients and clients; its
ability to engage consultants and healthcare practitioners and to operate its business and
increase referrals; the integration of prior acquisitions; the Group’s estimates for future
performance and its estimates regarding anticipated operating results; future revenue; capital
requirements; shareholder structure; and financing. In addition, even if the Group’s actual
results or development are consistent with the forward -looking statements contained in this
announcement, those results or developments may not be indicative of the Group’s results or
developments in the future. In some cases, forward -looking statements can be identified by
words such as “could”, “should”, “may”, “expects”, “aims”, “targets”, “anticipates”, “believes”,
“intends”, “estimates”, or similar. These forward -looking statements are based largely on the
Group’s current expectations as of the date of this announcement and are subject to a number
of known and unknown risks and uncertainties and other f actors that may cause actual results,
performance or achievements to be materially different f rom any future results, performance or
achievement expressed or implied by these forward -looking statements. In particular, the
Group’s expectations could be affected b y, among other things, uncertainties involved in the
integration of acquisitions or new developments; changes in legislation or the regulatory regime
governing healthcare in Switzerland, South Africa, Namibia and the UAE; poor performance by
healthcare practitioners who practise at its facilities; unexpected regulatory actions or
suspensions; competition in general; the impact of global economic changes; the impact of
pandemics, including COVID-19; and the Group’s ability to obtain or maintain accreditation or
approval for its facilities or service lines. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made in this announcement will in fact be
realised and no representation or warranty is given as to the completeness or accuracy of the
forward-looking statements contained in this announcement.

The Group is providing the information in this announcement as of this date, and disclaims any
intention to, and makes no undertaking to, publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South
Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and
the United Arab Emirates (“UAE”).

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.

At 30 June 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and
four day case clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern
Africa operations included 50 hospitals (three of which in Namibia), five sub -acute hospitals,
two mental health facilities and 12 day case clinics (four of which operated by Intercare) across
South Africa, and around 8 600 inpatient beds; and Mediclinic Middle East operated seven
hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in
the UAE. In addition, under management contracts, Mediclinic Middle East operates one
hospital in Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in mid –
2022.

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the UK, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the UK and listed on the LSE.

For further information, please contact:

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
[email protected]
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 03-09-2021 08:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (‘JSE’).
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.


Source link

About The Author

Related Posts